Carcinoma, Non-Small Cell Lung Clinical Trial
Official title:
Phase II Trial of Second Line Erlotinib + Digoxin in Patients With Non-Small Cell Lung Cancer
Verified date | March 2018 |
Source | University of Louisville |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the potential benefit of adding Digoxin to erlotinib (Tarceva) treatment for patients with non-small cell lung cancer.
Status | Terminated |
Enrollment | 26 |
Est. completion date | December 2010 |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - diagnosis of non-small cell lung cancer - measurable or evaluable disease - primary tumor must be documented by histopathic analysis - disease recurrences occurring greater than five years after original diagnosis must be biopsy proven - treatment with only one prior chemotherapy regimen for advanced disease (one additional prior regimen was allowed for neoadjuvant, adjuvant, or neoadjuvant plus adjuvant therapy) - serum creatinine < 2mg/dl, or a calculated creatinine clearance > 40cc/min using the following formula: (140-age) x WT(kg) x 0.85 (if female 0.72) x creatinine (mg/dl). Tests must be done within 28 days prior to registration - must have a CT scan (chest & abdomen) within 4 weeks prior to registration - Zubrod performance status of 0-3 Exclusion Criteria: - women who are pregnant or nursing - no other prior malignancy is allowed except for: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years - history of ventricular fibrillation, sinus node or AV nodal disease, Wolff Parkinson White Syndrome, evidence of congestive heart failure, chest pain with exertion, hemodynamically significant or life threatening cardiac arrhythmia, or evidence of prior myocardial infarction on EKG. EKG must have been done within 28 days prior to registration. A normal cardiac stress test within 182 days prior to registration is required for all patients over 50 years old or those with abnormal EKG or any history of cardiac disease. - hypersensitivity to erlotinib and/or Digoxin - abnormal levels of K, Mg, and/or Ca, or conditions which cause such abnormalities (e.g. malnutrition, severe diarrhea, prolonged vomiting, dialysis, GI suction, untreated hypothyroidism, and use of diuretics, amphotericin B, steroids, or antacids) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Louisville | James Graham Brown Cancer Center |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Therapeutic Response, Evaluated by Computed Tomography (CT) Scans of Chest & Abdomen. | Measured every 6 weeks after baseline until disease progression, an average of 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04486833 -
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
|
Phase 1/Phase 2 | |
Terminated |
NCT00321308 -
Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00190840 -
A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT01441128 -
-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05358249 -
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
|
Phase 1/Phase 2 | |
Terminated |
NCT02961283 -
Study of ASN003 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00973310 -
Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00385996 -
Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT02775006 -
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
|
Phase 3 | |
Completed |
NCT03232593 -
A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
|
||
Terminated |
NCT02590003 -
Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT01514864 -
Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
|
Phase 2 | |
Completed |
NCT00070629 -
CPG 7909 Injection in Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT02079636 -
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
|
Phase 1 | |
Terminated |
NCT01115803 -
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
|
Phase 1 | |
Completed |
NCT01079520 -
Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC)
|
N/A | |
Completed |
NCT00861627 -
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
|
Phase 2 | |
Completed |
NCT00923884 -
Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer
|
||
Recruiting |
NCT04389632 -
A Study of SGN-B6A in Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT03603652 -
NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung
|
N/A |